{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:17:07Z","timestamp":1768011427873,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12035-019-01763-x","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T13:02:54Z","timestamp":1568293374000},"page":"135-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl\/6j Mice"],"prefix":"10.1007","volume":"57","author":[{"given":"Gregory","family":"Oxenkrug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Summergrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"Suppl 1","key":"1763_CR1","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(Suppl 1):1\u201393","journal-title":"CNS Drugs"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.psychres.2016.01.02","volume":"237","author":"VA Chouinard","year":"2016","unstructured":"Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, \u00d6ng\u00fcr D (2016) Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res 237:304\u2013310. \nhttps:\/\/doi.org\/10.1016\/j.psychres.2016.01.02","journal-title":"Psychiatry Res"},{"key":"1763_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2009.05356.x","volume":"1199","author":"GF Oxenkrug","year":"2010","unstructured":"Oxenkrug GF (2010) Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci 1199:1\u201314. Review","journal-title":"Ann N Y Acad Sci"},{"key":"1763_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/ICM.1000105","volume":"1","author":"G Oxenkrug","year":"2017","unstructured":"Oxenkrug G, van der Hart M, Roeser J, Summergrad P (2017) Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients. Integr Clin Med 1:1\u20133","journal-title":"Integr Clin Med"},{"key":"1763_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-3-319-15630-9_8","volume-title":"Tryptophan metabolism: implications for biological processes, health and diseases, molecular and integrative toxicology","author":"G Oxenkrug","year":"2015","unstructured":"Oxenkrug G (2015) 3-hydroxykynurenic acid and type 2 diabetes: implications for aging, obesity, depression, Parkinson\u2019s disease and schizophrenia. In: Engin A, Engin AB (eds) Tryptophan metabolism: implications for biological processes, health and diseases, molecular and integrative toxicology. Springer International Publishing, Switzerland, pp. 173\u2013195. \nhttps:\/\/doi.org\/10.1007\/978-3-319-15630-9_8"},{"key":"1763_CR7","first-page":"1059","volume":"4","author":"G Oxenkrug","year":"2016","unstructured":"Oxenkrug G, van der Hart M, Roeser J, Summergrad P (2016) Anthranilic acid: a potential biomarker and treatment target for schizophrenia. Ann Psychiatry Ment Health 4:1059\u20131062","journal-title":"Ann Psychiatry Ment Health"},{"key":"1763_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12035-013-8497-4","volume":"48","author":"G Oxenkrug","year":"2013","unstructured":"Oxenkrug G (2013) Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 48:294\u2013301","journal-title":"Mol Neurobiol"},{"key":"1763_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1196\/annals.1403.003","volume":"1122","author":"GF Oxenkrug","year":"2007","unstructured":"Oxenkrug GF (2007) Genetic and hormonal regulation of the kynurenine pathway of tryptophan metabolism: new target for clinical intervention in vascular dementia, depression and aging. Ann N Y Acad Sci 1122:35\u201349","journal-title":"Ann N Y Acad Sci"},{"key":"1763_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 13:465\u2013477. \nhttps:\/\/doi.org\/10.1038\/nrn3257","journal-title":"Nat Rev Neurosci"},{"key":"1763_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep17799","volume":"5","author":"F Fazio","year":"2015","unstructured":"Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F et al (2015) Xanthurenic acid activates mGlu2\/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 5:17799. \nhttps:\/\/doi.org\/10.1038\/srep17799","journal-title":"Sci Rep"},{"key":"1763_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","volume":"50","author":"R Schwarcz","year":"2001","unstructured":"Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts R (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521\u2013530","journal-title":"Biol Psychiatry"},{"key":"1763_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.physbeh.2007.05.025","volume":"92","author":"S Erhardt","year":"2007","unstructured":"Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G (2007) The kynurenic acid hypothesis of schizophrenia. Physiol Behav 92:203\u2013209","journal-title":"Physiol Behav"},{"key":"1763_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.15761\/IMM.1000240","volume":"3","author":"G Oxenkrug","year":"2016","unstructured":"Oxenkrug G, Cornicelli J, van der Hart M, Roeser J, Summergrad P (2016) Kynurenic acid, an aryl hydrocarbon receptor ligand, is elevated in serum of Zucker fatty rats. Integr Mol Med 3:761\u2013763. \nhttps:\/\/doi.org\/10.15761\/IMM.1000240","journal-title":"Integr Mol Med"},{"key":"1763_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12035-015-9232-0","volume":"52","author":"GF Oxenkrug","year":"2015","unstructured":"Oxenkrug GF (2015) Increased plasma levels of xanthurenic and kynurenic acids in type 2 diabetes. Mol Neurobiol 52:805\u2013810. \nhttps:\/\/doi.org\/10.1007\/s12035-015-9232-0","journal-title":"Mol Neurobiol"},{"key":"1763_CR16","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1681\/ASN.2015070835","volume":"27","author":"R Korstanje","year":"2016","unstructured":"Korstanje R, Deutsch K, Bolanos-Palmieri P, Hanke N, Schroder P, Staggs L, Br\u00e4sen JH, Roberts ISD et al (2016) Loss of kynurenine 3-mono-oxygenase causes proteinuria. J Am Soc Nephrol 27:3271\u20133277","journal-title":"J Am Soc Nephrol"},{"key":"1763_CR17","first-page":"R135","volume":"303","author":"I Wolowczuk","year":"2012","unstructured":"Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, Taront S, Caiazzo R, Raverdy V et al (2012) Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Phys Regul Integr Comp Phys 303:R135\u2013R143","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"1763_CR18","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/oby.21199","volume":"23","author":"M Favennec","year":"2015","unstructured":"Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, Arredouani A, Marre M et al (2015) The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring) 23:2066\u20132074. \nhttps:\/\/doi.org\/10.1002\/oby.21199","journal-title":"Obesity (Silver Spring)"},{"key":"1763_CR19","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/0006-2952(77)90078-8","volume":"26","author":"D Bender","year":"1977","unstructured":"Bender D (1977) Effect of benserazide on tryptophan metabolism in the mouse. Biochem Pharmacol 26:1619\u20131623","journal-title":"Biochem Pharmacol"},{"key":"1763_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.taap.2016.03.011","volume":"300","author":"BJ Moyer","year":"2016","unstructured":"Moyer BJ, Rojas IY, Kerley-Hamilton LS, Harlett HF, Nemani KY, Trask HW, West RJ, Lupien LE et al (2016) Inhibition of aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2\/4, TGF\u00df, and IDO1. Toxicol Appl Pharmacol 300:13\u201324","journal-title":"Toxicol Appl Pharmacol"},{"key":"1763_CR21","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1093\/toxsci\/kfq024","volume":"115","author":"BC DiNatale","year":"2010","unstructured":"DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115:8997","journal-title":"Toxicol Sci"},{"key":"1763_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0006-2952(97)00150-0","volume":"54","author":"D Schrenk","year":"1997","unstructured":"Schrenk D, Riebniger D, Till M, Vetter S, Fiedler HP (1997) Tryptanthrins: A novel class of agonists of the aryl hydrocarbon receptor. Biochem Pharmacol 54:165\u2013171","journal-title":"Biochem Pharmacol"},{"key":"1763_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.15761\/IOD.1000142","volume":"2","author":"V Navrotskaya","year":"2016","unstructured":"Navrotskaya V, Oxenkrug G, Vorobyova L, Summergrad P (2016) Attenuation of high sucrose diet\u2013induced insulin resistance in ABC transporter deficient white mutant of Drosophila melanogaster. Integr Obesity Diabetes 2:187\u2013190. \nhttps:\/\/doi.org\/10.15761\/IOD.1000142","journal-title":"Integr Obesity Diabetes"},{"key":"1763_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.15761\/IOD.1000120","volume":"1","author":"V Navrotskaya","year":"2015","unstructured":"Navrotskaya V, Oxenkrug G, Vorobyova L, Summergrad P (2015) Attenuation of high sucrose diet\u2013induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster. Integr Obesity Diabetes 1:93\u201395. \nhttps:\/\/doi.org\/10.15761\/IOD.1000120","journal-title":"Integr Obesity Diabetes"},{"key":"1763_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbrc.2017.04.155","volume":"488","author":"O Muzik","year":"2017","unstructured":"Muzik O, Burghardt P, Yi Z, Kumar A, Seyoum B (2017) Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. Biochem Biophys Res Commun 488:29\u201332","journal-title":"Biochem Biophys Res Commun"},{"key":"1763_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-017-0530-4","volume":"36","author":"W Li","year":"2017","unstructured":"Li W, Zheng M, Wu S, Gao S, Yang M, Li Z, Min Q, Weiguang S et al (2017) Benserazide, a dopa decarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 36:58\u201370. \nhttps:\/\/doi.org\/10.1186\/s13046-017-0530-4","journal-title":"J Exp Clin Cancer Res"},{"key":"1763_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchemneu.2016.07.010","volume":"83-84","author":"A Nash","year":"2017","unstructured":"Nash A (2017) Crosstalk between insulin and dopamine signaling: a basis for the metabolic effects of antipsychotic drugs. J Chem Neuroanat 83-84:59\u201368","journal-title":"J Chem Neuroanat"},{"key":"1763_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2337\/dc11-0064","volume":"34","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA (2011) Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34:789\u2013794","journal-title":"Diabetes Care"},{"key":"1763_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","volume":"74","author":"T Pillinger","year":"2017","unstructured":"Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74:261\u2013269. \nhttps:\/\/doi.org\/10.1001\/jamapsychiatry.2016.3803","journal-title":"JAMA Psychiatry"},{"key":"1763_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11936-005-0007-1","volume":"7","author":"PC Deedwania","year":"2005","unstructured":"Deedwania PC, Volkova N (2005) Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med 7:61\u201374","journal-title":"Curr Treat Options Cardiovasc Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-019-01763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:46:54Z","timestamp":1599781614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-019-01763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-01763-x","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The results discussed here are the subject of a pending patent application.P. Summergrad is a non-promotional speaker for CME outfitters, Inc., and Pharmasquire and receives royalties from Springer, Harvard University Press, and the American Psychiatric Publishing. He is a consultant for Mental Health Data Services, Inc. and Quartet Health, Inc. The other author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}